ClinicalTrials.gg
CompletedNCT04171752Updated Aug 13, 2020

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

A Phase 1 interventional study of elafibranor in Geriatrics and Healthy, sponsored by Genfit. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Genfit · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the elderly, pharmacokinetics is altered. Gastric juice pH is elevated which influences drug solubility and absorption. Drug distribution is decreased in the elderly because of decreased cardiac output, increased peripheral vascular resistance, diminished blood flow in the liver and the kidneys, reduced total amount of water in the body. Drug metabolism and biotransformation mainly take place in the liver and is often reduced. Drug elimination is altered very often because of reduced excretory (renal and hepatic) function. All these changes may lead to significant pharmacokinetic changes in geriatric population. A formal pharmacokinetic clinical study is being conducted in order to assess the need of dose adjustment in the elderly population.

02

Conditions studied

  • Geriatrics
  • Healthy

Keywords

  • elafibranor
03

In context

Lead sponsor

Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For All Participants:
  1. Provide written prior to the conduct of any study related procedures;
  2. With a minimum body weight (BW) of 50 kg and within a (BMI) range of 18.0 to 30.0 kg/m\^2 (all inclusive) at Screening visit;
  3. Medically healthy as determined by the Investigator or medically qualified designee at both Screening and Inclusion visits. This will include no variation of BW of more than 5 percent between Screening and Inclusion visits;
  4. Absence of abnormalities identified by a detailed medical history and complete physical examination;
  5. Healthy participants, as determined by Normal Blood Pressure (BP) and Heart Rate (HR) at the screening and Inclusion visits after 5 minutes in supine position;
  6. Normal recording on a 12-lead ECG at the screening and Inclusion visits and no sign of any trouble of sinusal automatism, or considered as non clinically significant by investigator;
  7. Laboratory parameters within the normal range of the laboratory;
  8. Able to comprehend and willing to sign an Informed Consent Form, and to abide by the study restrictions;
  9. Non-smoker participant or smoker of not more than 5 cigarettes/day within 3 months prior to Inclusion visit, and able to restrain from smoking during the whole study duration;
  10. Participant with normal dietary habits;
  11. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research;

    • For Healthy Young Volunteers only:
  12. Males or females, between 18 and 45 years of age (all inclusive) at screening;
  13. Matched to healthy elderly participants by BMI (plus or minus 20 percent) and gender;
  14. Females participating in this study must be of non- or using highly efficient for the full duration of the study and for 1 month after the end of treatment;
  15. Females of childbearing potential must have a negative qualitative serum pregnancy test at Screening visit and a negative urine pregnancy test at Inclusion visit;

    • For Elderly volunteers only:
  16. Males or females aged 75 years old or older at Screening visit;
  17. Participants with mild, chronic, stable disease and stable treatment dose - no change in dose for the 3 months prior to Screening visit - (hypertension, hyperlipidemia, osteoarthritis, treated benign prostate hypertrophy, stable and treated hypothyroidism, treated glaucoma);
  18. Participants with suitable veins for cannulation or repeated venipuncture.

Exclusion criteria

Exclusion Criteria:

  • For all participants:
  1. Participants with a history of noncompliance to medical regimens;
  2. Participant who, in the opinion of the Investigator, is likely to be not respectful or not cooperative during the study, or unable to cooperate because of a language problem or a mental deficiency;
  3. Participant who cannot be contacted in case of emergency;
  4. Participant who is in the exclusion period of a previous study;
  5. Administrative or legal supervision;
  6. Inability to abstain from intensive muscular effort;
  7. Participant who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study;
  8. A positive alcohol test result or urine screen for drugs of abuse result at Screening or Inclusion visits;
  9. Any history or suspicion of alcohol abuse;
  10. Any history or suspicion of consumption of any drug of abuse (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, methamphetamines, methadone, methylenedioxymethamphetamine, opiates, tricyclic antidepressant), from screening to end of the study;
  11. Consumption of nutritional supplements, herb-containing drug preparations (including Chinese medicines) or other foods or beverages (e.g., grapefruit and xanthine-containing foods or beverages) that may affect drug-metabolizing enzymes or transporters from screening to end of the study visit;
  12. Evidence or history of gastrointestinal, hepatic, or renal disease, surgery or resection that would potentially alter absorption, distribution, metabolism, or excretion of orally administered drugs;
  13. Participants who have disease of cardiovascular, respiratory, renal, endocrine, hematological, gastrointestinal, neurological (central nervous system), psychiatric, systemic, infectious disorders or malignant tumor;
  14. General anesthesia within 3 months before administration;
  15. History or presence of allergy or unusual reactions to some drugs or anesthetics or known hypersensibility to the investigation product or its ;
  16. Major surgery within 28 days prior to Screening visit or major surgery planned within 6 months following participation to the study;
  17. Blood donation within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;
  18. Receipt of blood products within 2 months prior to Inclusion visit;
  19. Participants with symptomatic hypotension at Screening visit, whatever the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP ≥ 20 mmHg or DBP ≥ 10 mmHg within 3 minutes when changing from the supine to the standing position;
  20. Frequent headaches and/or migraines, recurrent nausea and/or vomiting;
  21. Participants who are positive for antibody, virus surface antigen, virus antibody;
  22. Significant, uncontrolled, or life-threatening condition or organ or disease;
  23. Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney disease) or estimated \<60 mL/min/1.73m²;
  24. Evidence of pelvic organ prolapsed, incontinence, or fistula of the urogenital system;
  25. Have a history of syncope, presyncope, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator;
  26. Any drug intake during the 2 weeks or 5 half-life of the drug preceding the first administration except those defined in concomitant medication section

    • For Young Adults Volunteers only:
  27. Females who are pregnant or breastfeeding. Female participants should not be enrolled if they plan to become pregnant during the time of study participation;
  28. Any medications (except paracetamol 3g/day or ) intake within the 2 weeks or 5 half-life prior to Screening visit;
  29. Evidence or history of clinically significant metabolic or allergic disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Young Adults

    Single oral dose of elafibranor 120mg

    Drug: elafibranor

  • Experimental
    Elderly

    Single oral dose of elafibranor 120mg

    Drug: elafibranor

Interventions

  • elafibranor 120mg is a coated tablet for oral administration

    Also known as: GFT505

06

What researchers measure

Primary outcomes

  1. Plasma pharmacokinetics: Area under curve from dosing time to infinity (AUC(0-∞)) of elafibranor and active metabolite

    In Healthy Young Adults compared to Healthy Elderly

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  2. Plasma pharmacokinetics: Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite

    In Healthy Young Adults compared to Healthy Elderly

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  3. Plasma pharmacokinetics: maximum plasma drug concentration (Cmax) of elafibranor and active metabolite

    In Healthy Young Adults compared to Healthy Elderly

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

Secondary outcomes

  1. Plasma pharmacokinetics: elimination half-life (t1/2)

    For elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  2. Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma

    For elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  3. Plasma pharmacokinetics: time of maximum observed concentration (tmax)

    For elafibranor and metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  4. Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)

    For other metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  5. Plasma pharmacokinetics: Area under curve from dosing time to infinity (AUC(0-∞))

    For other metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  6. Plasma pharmacokinetics: Area under curve from dosing time to last measurement (AUC(0-t))

    For other metabolites

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  7. Plasma pharmacokinetics: apparent volume of distribution (Vd/F)

    For elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  8. Plasma pharmacokinetics: renal clearance (CLr)

    For elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  9. Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)

    For elafibranor

    Time frame: pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose. Additionally, after elafibranor administration at 288 and 384 hours for elderly volunteers

  10. Urine pharmacokinetics: amount excreted (Ae)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  11. Urine pharmacokinetics: cumulative amount excreted (Ae0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  12. Urine pharmacokinetics: percentage of dose excreted (Fe)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  13. Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

  14. Urine pharmacokinetics: renal clearance (CLR)

    for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose

    Time frame: pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose

07

Study locations

1 site
  • BIOTRIAL
    Rennes, 35042, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Mar 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2019
First posted
Nov 21, 2019
StartActual
Nov 22, 2019
Primary completionActual
Mar 22, 2020
CompletionActual
Mar 30, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04171752
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Nov 22, 2019
Primary completion
Mar 22, 2020
Completion
Mar 30, 2020
Last update
Aug 13, 2020

Study contacts

Pascal Birman, MD
study director · Genfit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion